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background: Prokineticin-1 (PROK1) and connective tissue growth factor (CTGF) are expressed in human endometrium and ﬁrst-
trimester decidua and have individually been proposed to have roles in implantation and placentation. We have recently demonstrated
that CTGF may be a target gene for PROK1 in gene array analysis of a prokineticin receptor-1 stably transfected Ishikawa endometrial
epithelial cell line (PROKR1-Ishikawa). The ﬁrst aim of the study was to determine the effect of PROK1 on CTGF expression in
PROKR1-Ishikawa cells and ﬁrst-trimester decidua samples. Secondly, the effect of CTGF on trophoblast-derived HTR-8/SVneo cell
adhesion and network formation was investigated.
methods and results: Real-time qPCR showed that CTGF expression is elevated in ﬁrst-trimester decidua compared with non-
pregnant endometrium. In decidua, CTGF co-localized with PROKR1 to the glandular epithelium and a subset of stromal cells. PROK1
increased CTGF mRNA and protein expression in PROKR1-Ishikawa cells and ﬁrst-trimester human decidua (8–12 weeks gestation).
Knock down of endogenous PROK1 using micro RNA constructs targeted at PROK1, resulted in decreased expression of CTGF mRNA
and protein in decidua. Inhibitors of speciﬁc cell signalling molecules demonstrated that PROK1 regulates CTGF expression via the Gq, phos-
pholipase C (PLC), cSrc, epidermal growth factor receptor (EGFR), mitogen-activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) kinase pathway activation. Treatment of trophoblast-derived HTR-8/Svneo cells with 1 mg/ml CTGF signiﬁcantly increased
adhesion to collagen IV, and differentiation of the cells into tube-like structures in matrigel.
conclusions: CTGF expression in early pregnancy decidua is regulated by PROK1, via activation of the Gq, PLC, cSrc, EGFR, MAPK/
ERK kinase pathway. CTGF in turn may contribute to the regulation of trophoblast conversion of maternal spiral arteries.
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Introduction
During the ﬁrst trimester of normal pregnancy, extravillous tropho-
blast (EVT) cells attach to and then invade the maternal decidua
where they undergo endovascular transformation. These processes
occur ﬁrstly in order to anchor the fetus to the maternal endometrium
and secondly to remodel and replace the normal musculo-elastic
structure of the maternal spiral arteries with ﬁbrinoid material contain-
ing trophoblast. This results in conversion of the arteries into large
diameter, low resistance vessels that provide steady perfusion of the
villous trophoblast with maternal blood (Pijnenborg et al., 2006).
The process of trophoblast invasion and endovascular transformation
are tightly controlled spatially and temporally by factors released by
decidua and trophoblast including ﬁbroblast growth factor (FGF)
(Anteby et al., 2004), vascular endothelial growth factor-A (Schiessl
et al., 2009) and transforming growth factor-b1 (TGF-b1) (Lash
et al., 2005). Failure of trophoblast invasion and spiral artery trans-
formation has been implicated in the pathogenesis of conditions
such as pre-eclampsia and intrauterine growth restriction.
Prokineticin-1 (PROK1) is a pleiotropic protein that has recently
been described as having an important role in early pregnancy
(Hoffmann et al., 2006, 2009; Evans et al., 2008, 2009). During the
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prokineticin receptor-1 (PROKR1) are increased in decidua compared
with non-pregnant endometrium (Battersby et al., 2004; Evans et al.,
2008). Gene array analysis of an endometrial epithelial cell line
stably expressing PROKR1 (PROKR1-Ishikawa) recently demonstrated
that PROK1 differentially regulates a number of genes which are
known to be important in implantation and early pregnancy, including
cyclooxygenase-2, leukaemia inhibitory factor, interleukin (IL)-6, IL-8
and IL-11 (Evans et al., 2008, 2009; Cook et al., 2010). This therefore
led to the hypothesis that PROK1 may play an important role in the
establishment of early pregnancy (Evans et al., 2008).
The same gene array also identiﬁed connective tissue growth factor
(CTGF) as a target gene for PROK1 (Evans et al., 2008). CTGF is a
heparin-binding 38 kDa cysteine rich peptide that belongs to the
CCN (Cyr61, CTGF, Nov) family of secretory proteins. With a
broad spectrum of biological activities including cellular proliferation,
differentiation, adhesion, chemotaxis, migration, apoptosis and extra-
cellular matrix production, CTGF has major roles in many physiologi-
cal as well as pathological processes, including angiogenesis, tissue
repair, chondrogenesis, osteogenesis, cancer and ﬁbrosis (Bradham
et al., 1991; Brigstock, 2003). It is produced by, and capable of
acting upon numerous cell types, including human (Uzumcu et al.,
2000), mouse (Surveyor et al., 1998) and porcine (Moussad et al.,
2002) uterine tissue. Studies have also suggested that CTGF may
have a role in regulating implantation and placentation (Roh et al.,
2005; Rimon et al., 2008) with expression being increased in placentae
from women with pre-eclampsia compared with an uncomplicated
pregnancy (Oh et al., 2009). However, whether CTGF has a direct
effect on trophoblast biology has not been studied.
The current study therefore investigated PROK1 regulation of
CTGF and examined PROKR1 and CTGF localization in human preg-
nant and non-pregnant endometrial tissues. Furthermore, the signalling
pathway of PROK1-mediated CTGF expression was determined and
the potential effects of CTGF on important physiological events
during early pregnancy were investigated, speciﬁcally cell adhesion
and network formation, using the trophoblast-derived HTR-8/
SVneo cell line.
Materials and Methods
Reagents
Dulbecco’s modiﬁed Eagle’s medium (DMEM) F-12 Glutamax and
RPMI-1640 culture medium were purchased from Invitrogen Life
Technologies (Paisley, UK). Penicillin–streptomycin and fetal calf serum
(FCS) were purchased from PAA Laboratories Limited (Middlesex, UK).
Inhibitors of Gq (YM-254890, ﬁnal concentration 1 mM), phospholipase
C (PLC, U73122, ﬁnal concentration 10 mM), cSrc [4-amino-
5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d) pyrimidine (PP2), ﬁnal con-
centration 10 mM], matrix metalloprotease (MMP, GM6001, ﬁnal concen-
tration 10 mM), epidermal growth factor receptor (EGFR, AG1478, ﬁnal
concentration 200 nM), mitogen-activated protein kinase (MEK,
PD98059, ﬁnal concentration 50 mM) and nuclear factor of activated T
cells (NFAT, INCA 6, ﬁnal concentration 20 mM) were all purchased
from Calbiochem (Nottingham, UK) except YM-254890, a kind gift from
M Taniguchi, Astellas Pharma Inc. (Tsukuba, Japan). Prokineticin receptor
1 antibody was purchased from Lifespan Biosciences (Atlanta, GA, USA)
and the CTGF antibody was purchased from AbD Serotec (Kidlington,
UK) Recombinant human PROK1 and CTGF were purchased from Pepro-
tech (London, UK) and AbD Serotec, respectively. Alkaline phosphatase
secondary antibodies and bovine serum albumin (BSA) were purchased
from Sigma (Dorset, UK).
Patients and tissue collection
Endometrial biopsies (n ¼ 35) were collected with an endometrial suction
curette (Pipelle, Laboratoire CCD, Paris, France) from women of repro-
ductive age with regular menstrual cycles (21–30 days) who were under-
going surgery for benign gynaecological conditions. All women had not
taken any exogenous hormones in the 3 months preceding biopsy collec-
tion and none had any signiﬁcant gynaecological pathology, i.e. no con-
ﬁrmed endometriosis or any ﬁbroids greater than 3 cm in diameter.
Biopsies were dated by a pathologist according to the histological criteria
of Noyes et al. (1975). Furthermore, circulating progesterone and estradiol
levels, measured in serum samples collected from each patient at the time
of endometrial biopsy, were consistent for both the stated last menstrual
period and the histological assessment (data not shown). First-trimester
decidua (7–12 weeks gestation, n ¼ 25) was collected from women
undergoing elective ﬁrst-trimester surgical termination of pregnancy.
Ethical approval was obtained from Lothian Research Ethics Committee,
and written informed consent obtained before tissue collection.
At the time of collection, tissue biopsies were: (i) ﬁxed in neutral-
buffered formalin (4%) for 24 h, stored in 70% ethanol and wax
embedded; (ii) immersed in RNAlater (Ambion, Austin, TX, USA) and
stored at 2808C for subsequent RNA extraction and/or (iii) chopped
ﬁnely with scissors and transferred into serum-free DMEM-F-12 Gluta-
MAX, containing 100 IU penicillin and 100 mg/ml streptomycin for
culture.
Cell/tissue culture and treatment
Human Ishikawa endometrial epithelial cells (European Collection of Cell
Culture, Health Protection Agency, Porton Down, Wiltshire, UK), stably
transfected with PROKR1 (PROKR1-Ishikawa cells) were maintained in
DMEM F-12 GlutaMAX culture medium with 10% FCS, 100 IU penicillin
and 100 mg streptomycin and 200 mg/ml G418 antibiotic, at 378C and
5% CO2 as previously described (Evans et al., 2008). The human EVT cell-
line HTR-8/SVneo was a kind gift from Prof. Charles H. Graham, Queen’s
University, Kingston, Ontario, Canada and was maintained in RPMI con-
taining 5% FCS, 100 IU penicillin and 100 mg streptomycin at 378C and
5% CO2. First-trimester decidua isolated at surgical termination of preg-
nancy was chopped ﬁnely with scissors and maintained in serum-free
DMEM F-12 GlutaMAX containing 100 IU penicillin, and 100 mg/ml strep-
tomycin overnight at 378C and 5% CO2. Tissue was divided into equal
portions the following day for experimental procedures.
PROKR1-Ishikawa cells and decidua explants were incubated in serum-
free DMEM F-12 GlutaMAX containing 100 IU penicillin, and 100 mg/ml
streptomycin overnight at 378C and 5% CO2, before treatment with
40 nM PROK1 or vehicle, in the presence or absence of cell signalling
inhibitors. The treatment dose of PROK1 was based upon previous
dose–response ﬁndings of inositol phosphate mobilization in response
to PROK1 treatment in PROKR1-Ishikawa cells (Evans et al., 2008).
Cells were pre-treated with inhibitors for 1 h prior to PROK1 stimulation.
Cells, tissue and culture medium were harvested and RNA was extracted
for Taqman quantitative reverse transcription-PCR (qRT–PCR) and media
was stored for CTGF ELISA analysis.
Decidua tissue samples were infected with lentivirus expressing PROK1
miRNA constructs for 72 h as described by Evans et al. (2009). Oligonu-
cleotides encoding human PROK1 miRNA constructs were obtained from
Invitrogen and inserted into the pcDNA6.2-GW/EmGFP-miR vector and
used for transient transfections. These were recombined to create
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PROK1-72 and -287 (Evans et al., 2009). Following infection, tissue and
medium were harvested, and RNA was extracted for taqman qRT–PCR
and medium was stored for CTGF ELISA analysis.
Taqman qRT–PCR
CTGF expressions in PROKR1-Ishikawa cells and ﬁrst-trimester decidua
were measured by qRT–PCR analysis. RNA was extracted with Total
RNA Isolation reagent (Sigma) as per the manufacturer’s guidelines
using phase lock tubes (Eppendorf, Cambridge, UK). RNA samples
were reverse transcribed using MgCl2 (5.5 mM), deoxy (d)-NTPs
(0.5 mM each), random hexamers (2.5 mM), ribonuclease inhibitor
(0.4 U/ml) and multiscribe reverse transcriptase (1.25 U/ml; all from PE
Applied Biosystems, Warrington, UK) and samples were incubated for
90 min at 258C, 45 min at 488C and 5 min at 958C. A tube with no
reverse transcriptase was included to control for DNA contamination.
RT–PCR analysis was carried out using an ABI Prism 7900 (Applied
Biosystems, Foster City, CA, USA) with CTGF primers and FAM
(6-carboxyﬂuorescein)-labelled probe (forward: 5′-TGCACCGCCAAA
GATGGT-3′, reverse: 5′-GGCACGTGCACTGGTACTTG-3′, probe:
5′-TCCCTGCATCTTCGGTGGTACGGT-3′). Gene expression was
normalized to RNA loading using primers and VIC (Applied
Biosystems)-labelled probe for ribosomal 18S as an internal standard
(forward: 5′-CGGCTACCACATCCAAGGAA-3′, reverse: 5′-GCTGGAA
TTACCGCGGCT-3′,p r o b e :5 ′-TGCTGGCACCAGACTTGCCCTC-3′).
Results are expressed as relative to a positive RNA standard (cDNA
obtained from a single endometrial tissue) included in all reactions.
CTGF ELISA
CTGF protein secretion was analysed in the culture medium from
PROKR1-Ishikawa cells and decidua explants using an ELISA development
kit based on a sandwich ELISA format from Peprotech EC (London, UK),
as per the manufacturer’s instructions. Absorbance was detected by spec-
trophotometry, at 405 nm, with wavelength correction set at 650 nm. The
detection sensitivity for CTGF was 63 pg/ml. Data are presented as
mean+SEM from at least three individual experiments.
Immunoﬂuorescent microscopy
Co-localization of PROKR1 and CTGF in non-pregnant endometrium and
ﬁrst-trimester decidua was performed by dual ﬂuorescent immunohisto-
chemistry. Parafﬁn-embedded sections of 5 mm were dewaxed and rehy-
drated in graded ethanol. Antigen retrieval was performed by boiling in
0.01-M citrate buffer for 5 min, before endogenous peroxidase activity
was quenched with 3% H2O2/MeOH solution. Non-speciﬁc binding
sites were blocked using 5% normal goat serum, and then sections were
incubated with rabbit anti-CTGF (1:10 000 in blocking serum) overnight
at 48C. Control sections were incubated with an equivalent concentration
of normal immunoglobulin G from the same host species or blocking
serum without antibody to conﬁrm antibody speciﬁcity. CTGF immunor-
eactivity was detected with peroxidase-labelled goat anti-rabbit antibodies
(1:500 in blocking serum), followed by incubation with ﬂuorochrome
TSA-plus ﬂuorescein system (1:50 in substrate), producing a green ﬂuor-
escence. Sections were then boiled again in 0.01-M citrate buffer for
5 min to prevent non-speciﬁc binding of the second peroxidise antibody,
before re-blocking with 5% normal goat serum and incubation with
rabbit anti-human PROKR1 (1:500) overnight at 48C. PROKR1 immunor-
eactivity was detected with peroxidase-labelled goat anti-rabbit antibodies
(1:500) followed by ﬂuorochrome TSA-plus cyanide 3 System (1:50 in
substrate), producing a red ﬂuorescence. Sections were washed well
with phosphate-buffered saline (PBS) in between antibody incubations,
and counterstained with the nuclear speciﬁc ﬂuorescent label
4′,6′-diamidino-2-phenylindole (Sigma 1:1000 in PBS) and mounted in
PermaFluor ﬂuorescence mounting medium. Fluorescent images were
captured using a confocal laser scanning microscope (Meta Confocal;
Carl Zeiss, Jena, Germany).
HTR-8/SVneo adhesion assay
HTR-8/Svneo cells in suspension were treated with CTGF (1 mg/ml),
PROK1 (40 nM) or vehicle for 1 h, containing 1% serum. The concentrations
of CTGF and PROK1 treatment were based on dose–response ﬁndings of
cell adhesion to the extracellular matrix proteins (data not shown). Cells
were plated in triplicate at 5 × 10
4 cells/well on 96-well collagen I, collagen
IV, laminin or BSA (control)-coated CytoMatrix cell adhesion strips (Chemi-
con International, Inc.) according to the manufacturer’s instructions and incu-
bated at 378C for 45 min. Cells were rinsed three times with PBS containing
calcium and magnesium and stained for 5 min with 0.2% crystal violet dis-
solved in 10% ethanol. After ﬁve washes with PBS, crystal violet was
eluted with 0.1 M NaH2PO4 containing 50% ethanol for 15 min and the
optical densities were measured at 570 nm. Data are presented as
mean+SEM from at least three individual experiments.
HTR-8/SVneo network assay
Remodelling of maternal spiral arteries involves trophoblast invasion and
EVT differentiation, whereby EVT form a lining of the uterine vessels. Pre-
vious reports have shown that primary cytotrophoblast and HTR-8/Svneo
cells show endothelial cell-like behaviour in their ability to form networks
of tube-like structures when grown on matrigel (Dokras et al., 2001). We
used an in vitro culture system to investigate the effects of CTGF and
PROK1 on HTR-8/Svneo cell network formation. Transwell cell culture
inserts (diameter 12 mm, pore size 0.4 mM; Corning, Fisher Scientiﬁc
UK Ltd., Loughborough, UK) were coated with 100 ml growth factor
reduced Matrigel (BD Biosciences, Oxford, UK) and allowed to set at
378C for at least 30 min. 2.5 × 10
4 HTR-8/SVneo cells in cell culture
medium + 1% FCS were added to each insert and placed into a 12-well
plate containing culture medium and either vehicle, 1 mg/ml CTGF,
40 nM PROK1 or 50 ng/ml FGF-2 as a positive control in the lower
chamber. The concentrations of CTGF and PROK1 treatment were
based on dose–response ﬁndings of network formation (data not
shown). Cells were incubated at 378C with 5% CO2 for 18 h, then ﬁxed
in methanol, stained with haematoxylin and ﬁve areas from each well
were imaged using an Axiovert microscope (Zeiss) with ×10 magniﬁ-
cation. Images were blinded and the number of cell–cell protracted con-
tacts was counted as representations of the number of capillary-like
networks present in each ﬁeld. Each experiment was performed in dupli-
cate. Data are presented as the average number of networks per ﬁeld+
SEM from at least three separate experiments.
Statistics
All data are expressed as mean+SEM. Results were subjected to statisti-
cal analysis by one-way analysis of variance or Student’s t-tests as appro-
priate using Prism 5.0c (GraphPad Prism, San Diego, CA, USA) and
signiﬁcance was accepted when P , 0.05.
Results
PROK1 increases CTGF via Gq, PLC, cSrc,
EGFR, MEK signalling
To determine the effect of PROK1 on CTGF expression and release,
PROKR1-Ishikawa cells were treated with 40 nM PROK1 for up to
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fold-increase in CTGF mRNA expression compared with vehicle-
treated cells (7.4+1.6-fold; Fig. 1A; P , 0.05), which peaked by
12 h (13.9+3.3-fold; P , 0.001). CTGF protein secretion was signiﬁ-
cantly elevated after 12–48 h of treatment (48 h: 1819.1+122.7
versus 345.3+64.4 pg/ml; Fig. 1B; P , 0.001). CTGF is a TGF-b1
inducible gene in ﬁbroblasts, activated via a signalling cascade involving
PLC, cSrc and MEK (Kucich et al., 2001). To examine whether
PROK1 activates CTGF expression through a similar pathway,
PROKR1-Ishikawa cells were treated with 40 nM PROK1 alone or
with a panel of chemical inhibitors of cell signalling (Fig. 1C).
Co-treatment with PROK1 and inhibitors of Gq (YM-254890), PLC
(U73122), cSrc (PP2), MMP (GM6001), EGFR (AG1478) or MEK
(PD98059), for 6 h signiﬁcantly inhibited PROK1-mediated CTGF
mRNA expression (P , 0.05). An inhibitor of NFAT-calcineurin
association (INCA6) had no signiﬁcant effect on PROK1-mediated
CTGF mRNA expression.
CTGF is expressed in endometrium and
ﬁrst-trimester decidua and regulated in
decidua by PROK1
Since PROK1 and PROKR1 expressions are signiﬁcantly elevated in ﬁrst-
trimester decidua compared with non-pregnant endometrium, we
sought to investigate whether CTGF follows a similar pattern. Relative
expression of CTGF mRNA expression was signiﬁcantly higher in ﬁrst-
trimester decidua compared with non-pregnant endometrium (1.9+
0.49-fold; P , 0.01, Fig. 2A). There was no difference in CTGF
mRNA expression across different stages of the menstrual cycle
(data not shown). Immunoﬂuorescent histochemistry and confocal
microscopy were used to investigate the site of expression of CTGF
in relation to PROKR1. CTGF and PROKR1 both localized to glandular
epithelial cells in non-pregnant endometrium (Fig. 2B) and co-localized
to a subset of stromal cells in ﬁrst-trimester decidua (Fig. 2C).
We subsequently investigated the effect of PROK1 on CTGF
expression and release from ﬁrst-trimester decidua. Treatment of ﬁrst-
trimester decidua explants with 40 nM PROK1-increased CTGF mRNA
expression and protein secretion compared with vehicle-treated con-
trols after 24 (1.93+1.62-fold, Fig. 2D, P , 0.05) and 26 h, (1.56+
0.19-fold; Fig. 2E; P , 0.05; Fig. 2E), respectively. We conﬁrmed that
PROK1 regulates expression of CTGF in ﬁrst-trimester decidua using
PROK1-targeted miRNA lentivirus. First-trimester decidua was infected
with one of two miRNA constructs targeting PROK1 (pLenti6/
V5-EmGFP-hum-PROK1-72 or-287) or a negative scrambled control
lentivirus (as described in Evans et al., 2009). Infection of ﬁrst-trimester
decidua with either the pLenti6/V5-EmGFP-hum-PROK1-72 or -287
signiﬁcantly reduced levels of both CTGF mRNA (0.76+0.08-fold
and 0.74+0.03-fold; P , 0.01; Fig. 2F) and secreted CTGF (0.81+
0.07-fold and 0.72+0.06-fold; Fig. 2G) when compared with the
negative scrambled control construct.
CTGF promotes HTR-8/SVneo cell adhesion
to extracellular matrix
To investigate whether CTGF had an effect on the adhesion of tro-
phoblast to different extracellular matrix components, HTR-8/Svneo
cells were incubated on collagen I, collagen IV, ﬁbronectin or laminin
coated or uncoated wells. Treatment with 1 mg/ml CTGF signiﬁcantly
Figure 1 PROK1 increases CTGF mRNA and protein expression,
via Gq, PLC, cSrc, EGFR and MEK signalling in PROKR1-Ishikawa
cells. (A) CTGF mRNA and (B) protein expression in PROKR1-
Ishikawa cells after treatment with 40 nM PROK1. CTGF mRNA
expression peaked after 12 h and protein expression peaked after
48 h of PROK1 treatment. (C) Expression of CTGF mRNA was
measured after treatment with vehicle or 40 nM PROK1 in the
absence or presence of the speciﬁc cell signalling inhibitors
YM-254890 (Gq inhibitor; YM), U73122 (PLC inhibitor; U7), PP2
(cSrc inhibitor), GM1489 (matrix metalloproteinase inhibitor; GM),
AG1478 (EGFR inhibitor; AG), PD98059 (MEK inhibitor; PD) or inhibi-
tor of INCA6 (NFAT cells, inhibitor, INCA 6). PROK1-induced CTGF
mRNA expression was signiﬁcantly inhibited in the presence of these
inhibitors with the exception of INCA 6. Each bar represents the
mean+SEM of at least three independent experiments.
***P , 0.001, **P , 0.01, *P , 0.05 compared with vehicle treated
cells (A and B) or PROK1 treatment alone (C), as determined by
one-way ANOVA.
70 Waddell et al.Figure 2 CTGF expression and localization in human non-pregnant endometrium and ﬁrst-trimester decidua and regulation by PROK1 in ﬁrst-
trimester decidua. (A) CTGF mRNA expression is elevated in ﬁrst-trimester decidua (n ¼ 42) compared with non-pregnant endometrium
(n ¼ 30). (B) In non-pregnant endometrium (n ¼ 4; representative sections shown), double ﬂuorescence immunohistochemistry demonstrated
that CTGF (green panel) and PROKR1 (red panel) both localized to the glandular epithelium (G) and a subset of stromal cells (S). Negative
control (2ve) is indicated in the ﬁgure insert. (C) CTGF and PROKR1 co-localized in the glandular epithelium (G) and a subset of stromal cells
(S) in ﬁrst-trimester decidua. Co-localization shown in merge panel (×20 magniﬁcation). Treatment of ﬁrst-trimester decidua with 40 nM
PROK1-increased CTGF mRNA (n ¼ 10) (D) and protein expression (n ¼ 7) (E), after 24 and 26 h of treatment respectively. Conversely, ﬁrst-
trimester decidua infected with lentivirus encoding miRNA constructs targeting PROK1 (72 or 287)-decreased CTGF mRNA (F) and protein
expression (G) compared with control tissue infected with a scrambled miRNA sequence. ***P , 0.001, **P , 0.01, *P , 0.05 compared with non-
pregnant endometrium (A), vehicle-treated tissue (D and E) or compared with scrambled siRNA PROK1 construct (F and G), as determined by Stu-
dent’s t-test (A) or one-way ANOVA (D–G).
PROK1-regulated CTGF and trophoblast differentiation 71increased HTR-8/SVneo adhesion to collagen IV (1.4+0.07-fold
compared with vehicle-treated control; Fig. 3; P , 0.01), but not to
collagen I, ﬁbronectin or laminin (all P . 0.05). Similar studies using
40 nM PROK1 had no signiﬁcant effect on HTR-8/SVneo cell adhesion
to any of the matrices described (data not shown).
CTGF promotes HTR-8/SVneo cell network
formation
HTR-8/SVneo cells in matrigel were treated with 1 mg/ml CTGF or
50 ng/ml FGF-2, a positive angiogenic control (Hoffmann et al.,
2009). Compared with vehicle-treated controls, the number of net-
works was signiﬁcantly increased in cells treated with CTGF (9.3+
1.1 versus 3.1+0.5 networks per ﬁeld; Fig. 4A–C; P , 0.01) to a
similar level as treatment with FGF-2 (FGF-2; 9.3+1.1 versus
9.7+2.5 networks per ﬁeld; Fig. 4A, P , 0.01) for 18 h. Similar
studies using 40 nM PROK1 had no effect on HTR-8/SVneo cell
network formation (data not shown).
Discussion
This study demonstrates a novel role for PROK1 in early pregnancy in
mediating expression of CTGF. CTGF in turn may regulate important
physiologicaleventsinearlypregnancyincludingtrophoblastcelladhesion
and network formation involved in endovascular transformation of EVT.
UsingthePROKR1-Ishikawacellline,wedemonstratedthatPROK1regu-
latesCTGFexpressionviaGq,PLC,cSrc,EGFRandMEKsignalling.Next,
we demonstrated that CTGF expression is elevated in ﬁrst-trimester
decidua compared with non-pregnant endometrium and CTGF and
PROKR1 proteins are both localized to glandular epithelium and a
subset of stromal cells in human non-pregnant endometrium and
co-localized in ﬁrst-trimester decidua. Treatment of decidua with
PROK1-increased CTGF mRNA and protein expression and conversely,
inhibition of PROK1 expression reduced CTGF expression. Finally, using
the HTR-8/SVneo trophoblast cell line, we demonstrated that CTGF
promotes key processes involved in spiral artery remodelling, including
trophoblast adhesion to extracellular matrix, and network formation.
Figure 3 CTGF enhances HTR-8/Svneo cell adhesion. Treatment
of HTR-8/SVneo cells with 1 mg/ml CTGF-increased cell adhesion to
collagen IV, but not collagen I, ﬁbronectin or laminin. **P , 0.01 com-
pared with uncoated wells. Each experiment was carried out in tripli-
cate, and each bar represents the mean+SEM of at least three
different experiments.
Figure 4 CTGF induces network formation in trophoblast cell line
HTR-8/SVneo. (A) Treatment of HTR-8/SVneo cells with CTGF
increased the number of capillary-like network formations, as
scored by the number of protracted cell–cell contacts formed follow-
ing 18 h of treatment, to a similar level as caused by treatment with
the known pro-angiogenic factor FGF-2. Each experiment was carried
out in duplicate and each bar represents the mean+SEM of at least
three different experiments. **P , 0.01 compared with vehicle-
treated controls representative images of capillary-like network for-
mations by HTR-8/SVneo cells treated with vehicle (B) or CTGF
(C). Examples of capillary-like network formations are highlighted
by arrows in (B) and (C).
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an important role in early pregnancy by up-regulating key genes
involved in implantation and early placentation (Evans et al., 2008,
2009; Cook et al., 2010). Our studies have also suggested that
PROK1 may regulate the expression of CTGF. CTGF has been postu-
lated to have a role in implantation and placentation (Roh et al., 2005;
Rimon et al., 2008), however to our knowledge in humans, CTGF
regulation and function during the menstrual cycle and early pregnancy
had not been investigated. We found that PROK1 regulates CTGF
expression and secretion in cultured endometrial epithelial cells.
As the signalling pathway of TGF-b regulation of CTGF, involving
PLC, cSrc and MEK, is well documented in ﬁbroblasts (Kucich et al.,
2001; Leask et al., 2003), we sought to investigate whether the
same signalling pathway regulated PROK1-mediated CTGF expression
in endometrial epithelial cells. We demonstrate that PROKR1, a
Gq-coupled receptor that mediates extracellular signal-regulated
kinase 1/2 phosphorylation (Negri et al., 2005) also induces CTGF
expression via a cSrc-EGFR-MEK signalling pathway in
PROKR1-Ishikawa cells. In addition, inhibition of MMP, thereby pre-
venting cleavage of heparin-bound EGF and binding of EGF to its
receptor, also prevented PROK1-mediated CTGF expression,
further conﬁrming that PROK1 signals via this pathway to regulate
CTGF expression. However, inhibition of the calcium-calcineurin–
NFAT signalling pathway had no effect on PROK1-mediated CTGF
regulation. Although it is possible that the signalling pathways found
to be active in our PROKR1-Ishikawa cell line may have been inﬂu-
enced by their malignant transformation or genetic modiﬁcation to
express PROKR1, previous studies in our lab have shown that
responses from these cells are replicable in ex vivo explant studies
(Evans et al., 2008, 2009; Maldonado-Pe ´rez et al., 2009).
We also showed that CTGF expression is elevated in ﬁrst-trimester
decidua compared with non-pregnant endometrium. This ﬁnding is
consistent with our previous observations that PROK1 expression is
elevated in decidua compared with non-pregnant endometrium
(Evans et al., 2008) and further supports our ﬁndings that PROK1 is
responsible for elevated CTGF expression in ﬁrst-trimester decidua.
In contrast to PROK1, we saw no temporal regulation of CTGF
across the menstrual cycle, suggesting that CTGF is not under ster-
oidal or PROK1 regulation in human non-pregnant endometrium.
CTGF is regulated by TGF-b1 in other systems (Grotendorst et al.,
1996; Kothapalli et al., 1998; Hishikawa et al., 1999) and in pigs,
CTGF expression is highly correlated with that of TGF-b1 in uterine
tissues, indicating that CTGF may mediate some of the functions of
TGF-b1 in the reproductive tract during the oestrous cycle and preg-
nancy, such as stromal remodelling and angiogenesis (Moussad et al.,
2002). CTGF is also regulated by TNF-a (Cooker et al., 2007) and
EGF (Wenger et al., 1999), cytokines which are also elevated in
early pregnancy, therefore it is possible that PROK1 is not the only
regulator of uterine CTGF expression in early pregnancy.
We have shown CTGF protein expression in glandular epithelium of
non-pregnant endometrium, and glandular epithelium and stroma of
decidua from early pregnancy using ﬂuorescent immunohistochemis-
try. These ﬁndings are in agreement with those of Uzumcu et al.
(2000) and of Surveyor et al. (1998) in mice. We have further demon-
strated that CTGF co-localizes with PROKR1 in the glandular epi-
thelium of ﬁrst-trimester decidua, supporting a role for PROK1
regulation of CTGF in these cells in vivo during early pregnancy.
In order to conﬁrm the physiological relevance of our data, we
investigated the effect of PROK1 on CTGF expression in ﬁrst-
trimester decidua explants. Consistent with our observations in
the PROKR1-Ishikawa cell line, we showed that PROK1 regulates
CTGF mRNA expression and protein secretion in ﬁrst-trimester
decidua explants. We further conﬁrmed that PROK1 regulates
CTGF expression in ﬁrst-trimester decidua using miRNA constructs
targeting PROK1. In accordance with our ﬁnding that exogenous
PROK1 increases CTGF expression and protein secretion in
decidua explants, abrogation of endogenous PROK1 resulted in a
decrease in CTGF expression and protein secretion, conﬁrming
that PROK1 regulates basal expression and secretion of CTGF in
ﬁrst-trimester decidua.
Our data show that CTGF, but not PROK1, promotes trophoblast-
derived HTR-8/SVneo cell adhesion and formation of capillary-like
networks. Indeed CTGF increased the number of network formations
by HTR-8/SVneo cells to a similar level as the angiogenic factor FGF-2.
Although the higher number of networks may not necessarily equate
to functionality, the network formation assay demonstrates the
capacity of HTR-8/SVneo cells to exhibit an endovascular cell-like
phenotype. Functionally, therefore, we propose two novel activities
of PROK1-mediated CTGF up-regulation, ﬁrst, establishing the
ability of CTGF to promote trophoblast cell adhesion to the extra-
cellular matrix component collagen IV, and second, promoting EVT
cell tube-like network organization. For conversion of the spiral
arteries into wide bore low resistance vessels during the ﬁrst trimester
of pregnancy, EVT cells invade through the maternal decidua to the
spiral arteries, where they differentiate into tubule structures, lining
the wall of the arteries. Consistent with these requisite cellular
processes, CTGF has been shown to promote endothelial cell
adhesion, migration and proliferation in culture and to induce angio-
genesis in vivo (Kireeva et al., 1997; Shimo et al., 1998, 1999; Babic
et al., 1999).
Together these ﬁndings indicate that PROK1-mediated CTGF
secretion in endometrial epithelial cells may act upon trophoblast
cells in a paracrine manner to promote requisite cellular steps of tro-
phoblast conversion of maternal spiral arteries. Therefore disrupted
expression of PROK1 expression or signalling, and therefore of its
downstream target CTGF, may have implications for inadequate con-
version of the maternal spiral arteries, leading to placental abnormal-
ities or pre-eclampsia. This is consistent with the hypothesis proposed
by Oh et al. (2009) that CTGF may have a role in the pathophysiology
of placental injury or its sequelae including pre-eclampsia. However,
given the broad cellular range of CTGF functions, there are likely to
be many other biological processes, such as decidualization, tissue
remodelling and placentation that PROK1-mediated CTGF expression
may inﬂuence, and these remain to be investigated.
In conclusion, our ﬁndings extend previous work on the role of
PROK1 in early pregnancy, and suggest that PROK1 may be important
in regulating trophoblast conversion of maternal spiral arteries via
CTGF.
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